Table 2. Pairwise posthoc comparisons. .

Pairwise mean differences (mean ± 95% ci) between intact and reinnervated treatment cohorts (left), and between obstacle stride categories compared to level stride means, within treatment cohorts (intact/reinnervated). Bolding indicates statistical significance using FDR corrected threshold (p <= 0.0263). See Table 2—source data 1 for p-values.

Variable	Treatment cohort	Intact				Reinnervated
		S −1	S 0	Str +1	S +2	S −1	S 0	Str +1	S +2
Wnet	−0.47 ± 0.59	−0.91 ± 0.60	3.60 ± 0.57	0.00 ± 0.59	−0.86 ± 0.34	0.34 ± 0.55	3.88 ± 0.60	0.49 ± 0.70	−0.19 ± 0.46
Fpk	−0.02 ± 0.06	−0.04 ± 0.07	0.17 ± 0.06	0.04 ± 0.07	−0.04 ± 0.04	0.09 ± 0.06	0.62 ± 0.07	0.10 ± 0.08	0.05 ± 0.05
LpkF	−0.02 ± 0.04	−0.02 ± 0.01	0.10 ± 0.01	−0.01 ± 0.01	−0.02 ± 0.01	−0.05 ± 0.01	0.14 ± 0.01	−0.06 ± 0.02	−0.04 ± 0.01
VpkF	−1.89 ± 1.10	0.07 ± 0.45	−1.26 ± 0.43	0.00 ± 0.45	0.11 ± 0.26	0.60 ± 0.42	−0.39 ± 0.46	0.63 ± 0.53	0.81 ± 0.35
Tforce	0.02 ± 0.07	−0.01 ± 0.02	0.11 ± 0.02	−0.01 ± 0.02	−0.01 ± 0.01	−0.07 ± 0.02	0.07 ± 0.02	−0.06 ± 0.02	−0.06 ± 0.02
Tstride	0.00 ± 0.02	−0.01 ± 0.02	0.03 ± 0.02	−0.02 ± 0.02	0.01 ± 0.01	−0.07 ± 0.02	0.04 ± 0.02	−0.04 ± 0.03	−0.03 ± 0.02
Etot	0.01 ± 0.22	0.12 ± 0.18	0.76 ± 0.18	0.11 ± 0.18	0.12 ± 0.11	0.16 ± 0.17	0.74 ± 0.19	0.39 ± 0.22	0.09 ± 0.14
Efreq	55.70 ± 55.12	3.05 ± 9.44	−15.05 ± 9.04	−1.46 ± 9.34	−0.46 ± 5.43	−2.86 ± 8.75	−22.06 ± 9.52	−6.81 ± 11.04	−7.68 ± 7.28
Ephase	−0.06 ± 0.05	−0.01 ± 0.02	0.00 ± 0.02	0.00 ± 0.02	−0.01 ± 0.01	0.01 ± 0.02	0.04 ± 0.02	−0.01 ± 0.02	0.00 ± 0.01
Edur	0.08 ± 0.05	0.00 ± 0.03	0.04 ± 0.02	−0.01 ± 0.02	0.00 ± 0.01	−0.04 ± 0.02	−0.01 ± 0.03	0.00 ± 0.03	−0.03 ± 0.02